Sign up
Tech Capital

University of Kansas Medical Center orders another of Polarean’s 9820 Xenon Polariser systems

The hyperpolarised 129-Xenon gas helps to create a much stronger MRI signal, providing doctors with multiple images of lung structure and function
polarean's Xenon Polariser system
25 of Polarean’s polarisers are now either installed or on order

The University of Kansas Medical Center (KUMC) has placed an order for another of Polarean Imaging PLC’s (LON:POLX) 9820 Xenon Polariser system.

KUMC is a major research and teaching hospital and this polariser will form the cornerstone of a new hyperpolarised 129Xe imaging research programme.

WATCH: Polarean on track to complete enrolment for phase III trials

Following receipt of this latest order, Polarean now has a total of 25 polarisers either installed or on order.

“We are delighted to begin our relationship with KUMC and look forward to a long and mutually beneficial work programme which will aim to expand the clinical and public health frontiers of hyperpolarised xenon imaging,” said chief executive Richard Hullihen.

Better MRI scans

MRI scans generally aren’t very useful in assessing lung function, but Polarean is trying to change that. The company has developed a drug-device combination which uses hyperpolarised 129-Xenon gas MRI.

By inhaling and holding a small amount of the gas for just a few seconds, the patient is able to create a much stronger MRI signal, providing doctors with multiple images of lung structure and function.

Polarean, which is looking to sell the gas, the instrument which polarises the gas, and an associated quality assurance device, kicked off a trial of the technology last summer in two sites: Duke University and the University of Virginia and at the University of Cincinnati in June.

The trial is a 'head-to-head' non-inferiority trial testing 129Xe MRI against 133-Xenon (133Xe) scintigraphy.

In morning trading, Polarean shares were 4% higher at 20.80p.

 -- Adds share price --

View full POLX profile View Profile
View All

Related Articles

© tech Capital 2019

Tech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed tech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Tech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Technology market.